Compare EU & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | FHTX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.5M | 360.8M |
| IPO Year | N/A | 2020 |
| Metric | EU | FHTX |
|---|---|---|
| Price | $2.66 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $4.00 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 3.6M | 165.9K |
| Earning Date | 03-02-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,142,000.00 | $24,518,000.00 |
| Revenue This Year | $17.41 | $40.91 |
| Revenue Next Year | $95.45 | $11.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $2.95 |
| 52 Week High | $4.19 | $6.95 |
| Indicator | EU | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 48.10 |
| Support Level | $2.60 | $5.11 |
| Resistance Level | $2.90 | $5.79 |
| Average True Range (ATR) | 0.24 | 0.34 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 5.56 | 38.20 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.